Breast imaging with scintimammography

Orazio Schillaci, John R. Buscombe

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Carcinoma of the breast is the commonest form of cancer in women in most western countries: in the USA, it represents 32% of all invasive tumours in the female population. It is the second leading cause of death for women following lung cancer, accounting for 15% of all cancer deaths among women in the USA. In 2005, the American Cancer Society estimated 211,240 new cases and 40,410 female deaths from this disease (Jemal et al. 2005). Trends in incidence and mortality show that there has been a small, but steady annual increase in breast cancer (BC) incidence over the last 30 years, whereas the mortality rate has declined steadily since the beginning of the 1990s (Jemal et al. 2005). Early diagnosis is of the utmost importance to improve prognosis. Mammography (MM) is currently the best imaging modality for early detection of BC, and the results of several trials have demonstrated that mammographic screening can decrease the death rate due to BC (Daniel and Kopans 2004; Tabar et al. 2001). Nevertheless, this technique has some limitations that reduce its accuracy (Berlin 2001): not all BCs are evident on mammograms, especially in dense or dysplastic breasts (Birdwell et al. 2001), even palpable cancer may not be seen mammographically (Holland et al. 1983), it lacks of adequate specifi city in differentiating between malignant and benign lesions (Kopans 1992; Monusturi et al. 1991) and sometimes deciding which lesions require a biopsy may represent a challenge (Adler and Whal 1995). Excisional biopsy is the most effective method to determine the nature of breast abnormalities; however, the high number of biopsies in patients with benign breast lesions is a result of the low positive predictive value of MM (Kopans 1992). Breast ultrasound is largely used, but there are a few valid indications for this imaging technique, primarily involving the differentiation between cystic and solid masses and the evaluation of palpable lesions not visible on MM (Jackson 1990; Kopans 2004). Multiple areas of research have therefore been sought in order to select patients for biopsy and spare unnecessary surgical procedures. Among new imaging modalities, breast magnetic resonance imaging (MRI) and nuclear medicine breast imaging seem to be the most promising. Breast scintigraphy, also called, is a supplemental breast exam that may be used in some patients to investigate a breast abnormality. This nuclear medicine test is not a primary investigative tool for BC, but can be helpful in selected cases after mammography has been performed (Schillaci and Buscombe 2004; Schillaci 2005a).

Original languageEnglish
Title of host publicationBreast Cancer: Nuclear Medicine in Diagnosis and Therapeutic Options
PublisherSpringer Berlin Heidelberg
Pages57-70
Number of pages14
ISBN (Print)9783540367802
DOIs
Publication statusPublished - 2008

Fingerprint

Breast
Mammography
Breast Neoplasms
Biopsy
Nuclear Medicine
Mortality
Neoplasms
Unnecessary Procedures
Incidence
Berlin
Early Detection of Cancer
Radionuclide Imaging
Early Diagnosis
Cause of Death
Lung Neoplasms
Magnetic Resonance Imaging
Research
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Schillaci, O., & Buscombe, J. R. (2008). Breast imaging with scintimammography. In Breast Cancer: Nuclear Medicine in Diagnosis and Therapeutic Options (pp. 57-70). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-540-36781-9_6

Breast imaging with scintimammography. / Schillaci, Orazio; Buscombe, John R.

Breast Cancer: Nuclear Medicine in Diagnosis and Therapeutic Options. Springer Berlin Heidelberg, 2008. p. 57-70.

Research output: Chapter in Book/Report/Conference proceedingChapter

Schillaci, O & Buscombe, JR 2008, Breast imaging with scintimammography. in Breast Cancer: Nuclear Medicine in Diagnosis and Therapeutic Options. Springer Berlin Heidelberg, pp. 57-70. https://doi.org/10.1007/978-3-540-36781-9_6
Schillaci O, Buscombe JR. Breast imaging with scintimammography. In Breast Cancer: Nuclear Medicine in Diagnosis and Therapeutic Options. Springer Berlin Heidelberg. 2008. p. 57-70 https://doi.org/10.1007/978-3-540-36781-9_6
Schillaci, Orazio ; Buscombe, John R. / Breast imaging with scintimammography. Breast Cancer: Nuclear Medicine in Diagnosis and Therapeutic Options. Springer Berlin Heidelberg, 2008. pp. 57-70
@inbook{bb6f95b6708e4e8c81402d99fbe924cc,
title = "Breast imaging with scintimammography",
abstract = "Carcinoma of the breast is the commonest form of cancer in women in most western countries: in the USA, it represents 32{\%} of all invasive tumours in the female population. It is the second leading cause of death for women following lung cancer, accounting for 15{\%} of all cancer deaths among women in the USA. In 2005, the American Cancer Society estimated 211,240 new cases and 40,410 female deaths from this disease (Jemal et al. 2005). Trends in incidence and mortality show that there has been a small, but steady annual increase in breast cancer (BC) incidence over the last 30 years, whereas the mortality rate has declined steadily since the beginning of the 1990s (Jemal et al. 2005). Early diagnosis is of the utmost importance to improve prognosis. Mammography (MM) is currently the best imaging modality for early detection of BC, and the results of several trials have demonstrated that mammographic screening can decrease the death rate due to BC (Daniel and Kopans 2004; Tabar et al. 2001). Nevertheless, this technique has some limitations that reduce its accuracy (Berlin 2001): not all BCs are evident on mammograms, especially in dense or dysplastic breasts (Birdwell et al. 2001), even palpable cancer may not be seen mammographically (Holland et al. 1983), it lacks of adequate specifi city in differentiating between malignant and benign lesions (Kopans 1992; Monusturi et al. 1991) and sometimes deciding which lesions require a biopsy may represent a challenge (Adler and Whal 1995). Excisional biopsy is the most effective method to determine the nature of breast abnormalities; however, the high number of biopsies in patients with benign breast lesions is a result of the low positive predictive value of MM (Kopans 1992). Breast ultrasound is largely used, but there are a few valid indications for this imaging technique, primarily involving the differentiation between cystic and solid masses and the evaluation of palpable lesions not visible on MM (Jackson 1990; Kopans 2004). Multiple areas of research have therefore been sought in order to select patients for biopsy and spare unnecessary surgical procedures. Among new imaging modalities, breast magnetic resonance imaging (MRI) and nuclear medicine breast imaging seem to be the most promising. Breast scintigraphy, also called, is a supplemental breast exam that may be used in some patients to investigate a breast abnormality. This nuclear medicine test is not a primary investigative tool for BC, but can be helpful in selected cases after mammography has been performed (Schillaci and Buscombe 2004; Schillaci 2005a).",
author = "Orazio Schillaci and Buscombe, {John R.}",
year = "2008",
doi = "10.1007/978-3-540-36781-9_6",
language = "English",
isbn = "9783540367802",
pages = "57--70",
booktitle = "Breast Cancer: Nuclear Medicine in Diagnosis and Therapeutic Options",
publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Breast imaging with scintimammography

AU - Schillaci, Orazio

AU - Buscombe, John R.

PY - 2008

Y1 - 2008

N2 - Carcinoma of the breast is the commonest form of cancer in women in most western countries: in the USA, it represents 32% of all invasive tumours in the female population. It is the second leading cause of death for women following lung cancer, accounting for 15% of all cancer deaths among women in the USA. In 2005, the American Cancer Society estimated 211,240 new cases and 40,410 female deaths from this disease (Jemal et al. 2005). Trends in incidence and mortality show that there has been a small, but steady annual increase in breast cancer (BC) incidence over the last 30 years, whereas the mortality rate has declined steadily since the beginning of the 1990s (Jemal et al. 2005). Early diagnosis is of the utmost importance to improve prognosis. Mammography (MM) is currently the best imaging modality for early detection of BC, and the results of several trials have demonstrated that mammographic screening can decrease the death rate due to BC (Daniel and Kopans 2004; Tabar et al. 2001). Nevertheless, this technique has some limitations that reduce its accuracy (Berlin 2001): not all BCs are evident on mammograms, especially in dense or dysplastic breasts (Birdwell et al. 2001), even palpable cancer may not be seen mammographically (Holland et al. 1983), it lacks of adequate specifi city in differentiating between malignant and benign lesions (Kopans 1992; Monusturi et al. 1991) and sometimes deciding which lesions require a biopsy may represent a challenge (Adler and Whal 1995). Excisional biopsy is the most effective method to determine the nature of breast abnormalities; however, the high number of biopsies in patients with benign breast lesions is a result of the low positive predictive value of MM (Kopans 1992). Breast ultrasound is largely used, but there are a few valid indications for this imaging technique, primarily involving the differentiation between cystic and solid masses and the evaluation of palpable lesions not visible on MM (Jackson 1990; Kopans 2004). Multiple areas of research have therefore been sought in order to select patients for biopsy and spare unnecessary surgical procedures. Among new imaging modalities, breast magnetic resonance imaging (MRI) and nuclear medicine breast imaging seem to be the most promising. Breast scintigraphy, also called, is a supplemental breast exam that may be used in some patients to investigate a breast abnormality. This nuclear medicine test is not a primary investigative tool for BC, but can be helpful in selected cases after mammography has been performed (Schillaci and Buscombe 2004; Schillaci 2005a).

AB - Carcinoma of the breast is the commonest form of cancer in women in most western countries: in the USA, it represents 32% of all invasive tumours in the female population. It is the second leading cause of death for women following lung cancer, accounting for 15% of all cancer deaths among women in the USA. In 2005, the American Cancer Society estimated 211,240 new cases and 40,410 female deaths from this disease (Jemal et al. 2005). Trends in incidence and mortality show that there has been a small, but steady annual increase in breast cancer (BC) incidence over the last 30 years, whereas the mortality rate has declined steadily since the beginning of the 1990s (Jemal et al. 2005). Early diagnosis is of the utmost importance to improve prognosis. Mammography (MM) is currently the best imaging modality for early detection of BC, and the results of several trials have demonstrated that mammographic screening can decrease the death rate due to BC (Daniel and Kopans 2004; Tabar et al. 2001). Nevertheless, this technique has some limitations that reduce its accuracy (Berlin 2001): not all BCs are evident on mammograms, especially in dense or dysplastic breasts (Birdwell et al. 2001), even palpable cancer may not be seen mammographically (Holland et al. 1983), it lacks of adequate specifi city in differentiating between malignant and benign lesions (Kopans 1992; Monusturi et al. 1991) and sometimes deciding which lesions require a biopsy may represent a challenge (Adler and Whal 1995). Excisional biopsy is the most effective method to determine the nature of breast abnormalities; however, the high number of biopsies in patients with benign breast lesions is a result of the low positive predictive value of MM (Kopans 1992). Breast ultrasound is largely used, but there are a few valid indications for this imaging technique, primarily involving the differentiation between cystic and solid masses and the evaluation of palpable lesions not visible on MM (Jackson 1990; Kopans 2004). Multiple areas of research have therefore been sought in order to select patients for biopsy and spare unnecessary surgical procedures. Among new imaging modalities, breast magnetic resonance imaging (MRI) and nuclear medicine breast imaging seem to be the most promising. Breast scintigraphy, also called, is a supplemental breast exam that may be used in some patients to investigate a breast abnormality. This nuclear medicine test is not a primary investigative tool for BC, but can be helpful in selected cases after mammography has been performed (Schillaci and Buscombe 2004; Schillaci 2005a).

UR - http://www.scopus.com/inward/record.url?scp=84892280375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892280375&partnerID=8YFLogxK

U2 - 10.1007/978-3-540-36781-9_6

DO - 10.1007/978-3-540-36781-9_6

M3 - Chapter

AN - SCOPUS:84892280375

SN - 9783540367802

SP - 57

EP - 70

BT - Breast Cancer: Nuclear Medicine in Diagnosis and Therapeutic Options

PB - Springer Berlin Heidelberg

ER -